FDA approvals can have a profound impact on pharmaceutical companies, especially when it allows them to tap into new market segments. For Aquestive Therapeutics, this approval not only validates the safety and efficacy of Libervant Buccal Film for a younger demographic but also potentially opens up new revenue streams. Given the specificity of the approval for pediatric patients, this could position AQST as a leader in this niche, assuming the product is well-received and adopted by healthcare providers.